Subject(s)
Brain Diseases/diagnosis , Dysphonia/diagnosis , Hyperalgesia/diagnosis , Medulla Oblongata/physiopathology , Aged , Brain Diseases/pathology , Brain Diseases/physiopathology , Dysphonia/pathology , Dysphonia/physiopathology , Female , Humans , Hyperalgesia/pathology , Hyperalgesia/physiopathology , Medulla Oblongata/pathology , SyndromeABSTRACT
BACKGROUND AND AIM: The efficiency of tele-monitoring or tele-assistance in patients with severe chronic ventilatory failure in home mechanical ventilation (HMV) is still being investigated. Our aim was to test the feasibility of a model which consisted in: 1) once a week nocturnal telemonitoring, supervised by a doctor in charge in a Respiratory Intensive Care Unit, who also provided a telephone-counselling (24/7) on demand; 2) a scheduled visit every two months. METHODS: A 2-year observational study was carried out on 16 patients ventilated for at least 1 year and for > or = 8 hours/day. Once a week patients underwent a nocturnal monitoring during HMV. The compliance was evaluated by regular transmission of data and regular follow-up, the level of satisfaction by a telephone-questionnaire. RESULTS: The adherence to the protocol study was good in 9/16 (56%) and poor in 7/16 (44%) patients. For each patient, the mean number of connections was 46.12 +/- 36.39 (70.7% of that expected), in those with good compliance it increased to 63.8 +/- 32.7 (114% of that expected). The median hours of connection was 343 (138-1019) and 89 (0-521) for patients with good and poor compliance respectively, p = 0.038. The mean scheduled visits for patient with good compliance was 6.9 +/- 4.14 (100% of that expected). Emergency visits were avoided in 62.5% of cases. The satisfaction score was higher in compliant versus non compliant patients (p = 0.019). CONCLUSION: This pilot study showed that the telemonitoring system employed was feasible and effective in more compliant patients who claimed a high rate of satisfaction.
Subject(s)
Respiratory Insufficiency/physiopathology , Telemetry/methods , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Middle Aged , Patient Compliance , Pilot Projects , Retrospective Studies , Young AdultABSTRACT
OBJECTIVE: To compare iron lung (ILV) versus mask ventilation (NPPV) in the treatment of COPD patients with acute on chronic respiratory failure (ACRF). DESIGN: Randomised multicentre study. SETTING: Respiratory intermediate intensive care units very skilled in ILV. PATIENTS AND METHODS: A total of 141 patients met the inclusion criteria and were assigned: 70 to ILV and 71 to NPPV. To establish the failure of the technique employed as first line major and minor criteria for endotracheal intubation (EI) were used. With major criteria EI was promptly established. With at least two minor criteria patients were shifted from one technique to the other. RESULTS: On admission, PaO(2)/FiO(2), 198 (70) and 187 (64), PaCO(2), 90.5 (14.1) and 88.7 (13.5) mmHg, and pH 7.25 (0.04) and 7.25 (0.05), were similar for ILV and NPPV groups. When used as first line, the success of ILV (87%) was significantly greater (P = 0.01) than NPPV (68%), due to the number of patients that met minor criteria for EI; after the shift of the techniques; however, the need of EI and hospital mortality was similar in both groups. The total rate of success using both techniques increased from 77.3 to 87.9% (P = 0.028). CONCLUSIONS: The sequential use of NPPV and ILV avoided EI in a large percentage of COPD patients with ACRF; ILV was more effective than NPPV on the basis of minor criteria for EI but after the crossover the need of EI on the basis of major criteria and mortality was similar in both groups of patients.
Subject(s)
Intensive Care Units , Masks , Oxygen/therapeutic use , Positive-Pressure Respiration/instrumentation , Pulmonary Disease, Chronic Obstructive/therapy , Respiration, Artificial/instrumentation , Acute Disease , Aged , Chronic Disease , Cross-Over Studies , Female , Humans , Inhalation , Intermediate Care Facilities , MaleABSTRACT
No disponible
No disponible
Subject(s)
Humans , Tobacco Smoke Pollution/prevention & control , Smoking/legislation & jurisprudence , Tobacco Use Disorder/prevention & control , Smoking Cessation/statistics & numerical data , Italy , Law Enforcement , AttitudeABSTRACT
AIM: We hypothesize that different patterns of chest wall (CW) kinematics and respiratory muscle coordination contribute to sensation of dyspnoea during unsupported arm exercise (UAE) and leg exercise (LE). METHODS: In six volunteer healthy subjects, we evaluated the volumes of chest wall (V(cw)) and its compartments, the pulmonary apposed rib cage (V(rc,p)), the diaphragm-abdomen apposed rib cage (V(rc,a)) and the abdomen (V(ab)), by optoelectronic plethysmography. Oesophageal, gastric and trans-diaphragmatic pressures were simultaneously measured. Chest wall relaxation line allowed the measure of peak rib cage inspiratory muscle, expiratory muscle and abdominal muscle pressures. The loop V(rc,p)/V(rc,a) allowed the calculation of rib cage distortion. Dyspnoea was assessed by a modified Borg scale. RESULTS: There were some differences and similarities between UAE and LE. Unlike LE with UAE: (i) V(cw) and V(rc,p) at end inspiration did not increase, whereas a decrease in V(rc,p) contributed to decreasing CW end expiratory volume; (ii) pressure production of inspiratory rib cage muscles did not significantly increase from quiet breathing. Not unlike LE, the diaphragm limited its inspiratory contribution to ventilation with UAE with no consistent difference in rib cage distortion between UAE and LE. Finally, changes in abdominal muscle pressure, and inspiratory rib cage muscle pressure predicted 62% and 41.4% of the variability in Borg score with UAE and LE, respectively (P < 0.01). CONCLUSION: Leg exercise and UAE are associated with different patterns of CW kinematics, respiratory muscle coordination, and production of dyspnoea.
Subject(s)
Dyspnea/physiopathology , Exercise/physiology , Respiratory Muscles/physiology , Thoracic Wall/physiology , Abdominal Muscles/physiology , Adult , Analysis of Variance , Arm , Biomechanical Phenomena , Esophagus/physiology , Humans , Leg , Linear Models , Male , Movement , Pressure , Pulmonary Gas Exchange , Respiratory Mechanics/physiology , Ribs , Stomach/physiologyABSTRACT
BACKGROUND AND AIM: Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries. The aim of this study was to assess the effects and the advantages of a combined dietary supplementation with PUFA n-3, vitamin E, niacin and gamma-oryzanol on lipid profile, inflammatory status and oxidative balance. METHODS AND RESULTS: Fifty-seven dyslipidemic volunteers were randomly assigned to receive: placebo (group A, 19 subjects); PUFA n-3 and vitamin E (group B, 18 subjects); the same as B plus gamma-oryzanol and niacin (group C, 20 subjects). Lipid profile, reactive oxygen species (ROS), total antioxidant capacity (TAC), vitamin E, interleukin 1-beta (IL1-beta), tumor necrosis factor (TNF-alpha) and thromboxane B2 (TXB2) were determined at baseline (T0) and after four months (T1). All dyslipidemic subjects showed, at baseline, oxidative stress and, after four months, all biochemical markers improved significantly in groups treated with dietary supplementation. Particularly in group C all lipid patterns improved significantly. CONCLUSIONS: Our findings demonstrate that the strategy of combining different compounds, which protect each other and act together at different levels of the lipid chain production, improves lipid profile, inflammatory and oxidative status, allowing us to reduce the dose of each compound under the threshold of its side effects.
Subject(s)
Antioxidants/therapeutic use , Hyperlipidemias/drug therapy , Hypolipidemic Agents/therapeutic use , Lipid Metabolism/drug effects , Oxidative Stress/drug effects , Adult , Aged , Antioxidants/administration & dosage , Atherosclerosis/epidemiology , Atherosclerosis/etiology , Cytokines/metabolism , Dietary Supplements , Drug Therapy, Combination , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/therapeutic use , Female , Humans , Hyperlipidemias/complications , Hypolipidemic Agents/administration & dosage , Inflammation Mediators/metabolism , Male , Middle Aged , Niacin/administration & dosage , Niacin/therapeutic use , Oxidation-Reduction , Phenylpropionates/administration & dosage , Phenylpropionates/therapeutic use , Reactive Oxygen Species/metabolism , Risk Factors , Vitamin E/administration & dosage , Vitamin E/therapeutic useABSTRACT
New diagnostic and therapeutic aspects of the essential thrombocythemia are summarized. A series of 14 patients with essential thrombocythemia is reported.
Subject(s)
Thrombocythemia, Essential , Adult , Aged , Biopsy , Bone Marrow/pathology , Female , Humans , Male , Megakaryocytes/cytology , Middle Aged , Platelet Count , Retrospective Studies , Survival Analysis , Thrombocythemia, Essential/diagnosis , Thrombocythemia, Essential/drug therapyABSTRACT
BACKGROUND: To date we lack official data on tipology of Diagnosis Related Groups (DRGs) and their quality in Italian Respiratory Intermediate Care Units (RICUs). AIM: The objective of the study was to collect data on the activity of 26 Italian RICUs and to evaluate the quality of the DRGs generated. METHODS: The primary and secondary diseases, the procedures carried out and their coding using the ICD9 system (valid Italy until 2000) were collected from the discharge forms of patients admitted to RICUs. To obtain the DRG, these codes were automatically recoded in the ICD9-CM classification system by Grouper 10. Afterwards, the same diseases and procedures were directly processed by the ICD9-CM classification system. Finally, in order to evaluate the quality of care, the DRGs generated by the ICD9 classification system were compared to DRGs generated by the ICD9-CM classification system. RESULTS: The average weight of the patients cared for in an Italian RICU was 2.05 using the ICD9 classification system and 2.53 using the ICD9-CM classification system. Some non-complicated DRGs (80-97) or non specific DRGs (101-102) were set to zero; others, like DRG 87 appear due to the ability of the ICD9-CM classification system to recognise and accept the fifth digit of the Respiratory Failure code (518.81). The difference in terms of DRG scores generated by the two codification systems was 360.5 DRG points in favour of ICD9-CM. More than 1 million Euro of reimbursements have been lost, as the average national reimbursement for each DRG score is Euro 2,943.80. CONCLUSION: Severe pulmonary diseases determined the case mix of patients cared for in the Italian RICUs during the observed period. The Italian RICUs offer high quality assistance and are characterised by high mean weight per treated patient. However, the activity has been under-estimated due to the low sensitivity of the ICD9 classification system used in the recognition of the real disease and in the correct generation of relative DRG. The ICD9 classification system penalised the recognition of respiratory failure in particular.
Subject(s)
International Classification of Diseases/standards , Respiratory Care Units/statistics & numerical data , Respiratory Tract Diseases/diagnosis , Aged , Evaluation Studies as Topic , Female , Humans , Italy , Male , Middle Aged , Respiratory Care Units/standardsABSTRACT
The aim of this randomised study was to compare the effects of iron lung ventilation (ILV) with invasive mechanical ventilation (IMV) in patients with acute respiratory failure (ARF) due to exacerbation of chronic obstructive pulmonary disease. Forty-four patients with ARF were assigned either to ILV (22 patients) or IMV (22 patients). Primary end-points were the improvement in gas exchange and complications related to mechanical ventilation. On admission ILV and IMV groups did not differ in age, simplified acute physiology score II, arterial oxygen tension (Pa,O2)/inspiratory oxygen fraction (FI,O2), arterial carbon dioxide tension (Pa,CO2) and pH. Compared with baseline, ILV and IMV induced a similar and significant improvement in Pa,O2/FI,O2, Pa,CO2 and pH after 1 h of treatment and at discontinuation of mechanical ventilation. Major complications tended to be more frequent in patients treated with IMV than in those treated with ILV (27.3% versus 4.5%), whereas mortality rate was similar (27.3% versus 18.2%). The ventilator-free days and the length of hospital stay were significantly lower in the ILV than in the IMV group. This study suggests that iron lung ventilation is as effective as invasive mechanical ventilation in improving gas exchange in chronic obstructive pulmonary disease patients with acute respiratory failure, and is associated with a tendency towards a lower rate of major complications.
Subject(s)
Positive-Pressure Respiration , Pulmonary Disease, Chronic Obstructive/therapy , Respiration, Artificial/methods , Respiratory Insufficiency/therapy , Ventilators, Negative-Pressure , Acute Disease , Aged , Female , Humans , Intubation, Intratracheal , Length of Stay , Male , Pilot Projects , Prospective Studies , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Gas Exchange , Respiration, Artificial/adverse effects , Respiratory Insufficiency/etiologyABSTRACT
40 subjects who had a transitory ischemic cerebral attack were treated with Mesoglycan and controlled for two consecutive years. Only four patients showed relapse of ischemic cerebral attacks. There was also noted a positive effect on the patients' quality of life, examined using psycometric scales.
Subject(s)
Glycosaminoglycans/therapeutic use , Ischemic Attack, Transient/drug therapy , Administration, Oral , Aged , Aged, 80 and over , Follow-Up Studies , Glycosaminoglycans/administration & dosage , Humans , Male , Middle Aged , Psychometrics , Quality of Life , Time FactorsABSTRACT
BACKGROUND: Several large controlled trials have shown that beta blockers given to patients with heart failure (New York Heart Association functional class II-IV) reduce morbidity and mortality. Despite these impressive results, implementing the use of beta blockade in clinical practice appears slow and difficult. The BRING-UP study was designed to tackle this problem. OBJECTIVES: To accelerate the adoption of beta blockade in clinical practice; to provide an epidemiological estimate of the proportion of patients with heart failure suitable for this treatment in general cardiology care; and to assess effectiveness of these drugs outside the setting of clinical trials. METHODS: The design of the study and recommendations derived from available evidence on the use of beta blockers were discussed with cardiologists during regional meetings. All consecutive heart failure patients in a one month period, whether treated or not with beta blockers, were eligible for the study. In each patient, the decision to prescribe a beta blocker was a free choice for the participating physicians. All centres were provided with carvedilol, metoprolol, and bisoprolol at appropriate doses; the choice of the drug and dosage was left to the responsible clinician. All patients were followed for one year. RESULTS: 197 cardiological centres enrolled 3091 patients, 24.9% of whom were already on beta blocker treatment at baseline. beta Blockers were newly prescribed in 32.7% of cases, more often in younger and less severely ill patients. The mean daily dose of the drugs used at one year corresponded to about 70% of the maximum dose used in clinical trials. Starting treatment with beta blockers did not affect the prescription or dosage of other recommended drugs. The overall rate of beta blocker treatment increased over the year of the study from 24.9% to 49.7%. During the 12 month period, 351 deaths occurred (11.8%). In multivariate analysis, the use of beta blockers was independently associated with a better prognosis, with a relative risk of 0.60 and a lower incidence of hospital admissions for worsening heart failure. CONCLUSIONS: The implementation of beta blockers in clinical practice is feasible and could be accelerated. These drugs are associated with a lower mortality and reduced hospital admission rates, not only in clinical trials but also in the normal clinical setting.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Cardiac Output, Low/drug therapy , Aged , Bisoprolol/therapeutic use , Carbazoles/therapeutic use , Cardiac Output, Low/mortality , Carvedilol , Chronic Disease , Contraindications , Female , Follow-Up Studies , Humans , Male , Metoprolol/therapeutic use , Middle Aged , Multivariate Analysis , Professional Practice , Propanolamines/therapeutic use , Treatment OutcomeABSTRACT
The effects of Citicoline were investigated in 40 patients with pathological cerebral involution of atrophic origin. The dose was 1000 mg/die by parenteral injection for 4 weeks; 20 patients, after a wash-out of a week, received another cycle of Citicoline at the same doses for other 4 weeks. Citicoline treatment has shortened significantly the reaction times and has improved cognitive and behaviour capacities, evaluated according to the "Clifton test" and "Green Relatives Stress Scale". Better results were obtained in patients who received two cycles of therapy. No side effects were observed during the study.
Subject(s)
Cytidine Diphosphate Choline/therapeutic use , Nootropic Agents/therapeutic use , Reaction Time/drug effects , Aged , Aged, 80 and over , Female , Humans , Male , Time FactorsABSTRACT
Negative-pressure ventilation (NPV) was the primary mode of assisted ventilation for patients with acute respiratory failure until the Copenhagen polio epidemic in the 1950s, when, because there was insufficient equipment, it was necessary to ventilate patients continually by hand via an endotracheal tube. Thereafter, positive-pressure ventilation was used routinely. Since it was also observed that patients with obstructive sleep apnoea could be treated noninvasively with positive pressure via a nasal mask, noninvasive positive-pressure ventilation (NPPV) has become the most widely used noninvasive mode of ventilation. However, NPV still has a role in the treatment of certain patients. In particular, it has been used to good effect in patients with severe respiratory acidosis or an impaired level of consciousness, patients that to date have been excluded from all prospective controlled trials of NPPV. NPV may be used in those who cannot tolerate a facial mask because of facial deformity, claustrophobia or excessive airway secretion. NPV has also been used successfully in small children, and beneficial effects on the cardiopulmonary circulation maybe a particular advantage in children undergoing complex cardiac reconstructive surgery. This review is divided into two parts: the first is concerned with the use of negative-pressure ventilation in the short term, and the second with its use in the long term.
Subject(s)
Respiratory Insufficiency/therapy , Ventilators, Negative-Pressure/adverse effects , Acute Disease , Adolescent , Adult , Child , Child, Preschool , Chronic Disease , Contraindications , Humans , Infant , Infant, Newborn , Middle Aged , Outcome Assessment, Health Care , Respiratory Insufficiency/nursingABSTRACT
BACKGROUND: The lack of patient triggering capability during negative pressure ventilation (NPV) may contribute to poor patient synchrony and induction of upper airway collapse. This study was undertaken to evaluate the performance of a microprocessor based iron lung capable of thermistor triggering. METHODS: The effects of NPV with thermistor triggering were studied in four normal subjects and six patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) by measuring: (1) the time delay (TDtr) between the onset of inspiratory airflow and the start of assisted breathing; (2) the pressure-time product of the diaphragm (PTPdi); and (3) non-triggering inspiratory efforts (NonTrEf). In patients the effects of negative extrathoracic end expiratory pressure (NEEP) added to NPV were also evaluated. RESULTS: With increasing trigger sensitivity the mean (SE) TDtr ranged from 0.29 (0.02) s to 0.21 (0.01) s (mean difference 0.08 s, 95% CI 0.05 to 0.12) in normal subjects and from 0.30 (0.02) s to 0.21 (0.01) s (mean difference 0.09 s, 95% CI 0.06 to 0.12) in patients with COPD; NonTrEf ranged from 8.2 (1.8)% to 1.2 (0.1)% of the total breaths in normal subjects and from 11.8 (2.2)% to 2.5 (0.4)% in patients with COPD. Compared with spontaneous breathing, PTPdi decreased significantly with NPV both in normal subjects and in patients with COPD. NEEP added to NPV resulted in a significant decrease in dynamic intrinsic PEEP, diaphragm effort exerted in the pre-trigger phase, and NonTrEf. CONCLUSIONS: Microprocessor based iron lung capable of thermistor triggering was able to perform assist NPV with acceptable TDtr, significant unloading of the diaphragm, and a low rate of NonTrEf. NEEP added to NPV improved the synchrony between the patient and the ventilator.
Subject(s)
Microcomputers , Pulmonary Disease, Chronic Obstructive/therapy , Respiration, Artificial/instrumentation , Respiratory Insufficiency/therapy , Ventilators, Negative-Pressure , Adult , Aged , Functional Residual Capacity/physiology , Humans , Male , Middle Aged , PressureABSTRACT
30 patients, affected by chronic ethylic hepatopathy, were treated with 450 mg/daily of ursodeoxycholic acid (UDCA): after six months, a significant decrease of serum hepatic enzymes was noted. The addition of silymarin (400 mg/daily) to UDCA in other 30 patients, induced a further improvement of hepatic function.
Subject(s)
Antioxidants/therapeutic use , Cholagogues and Choleretics/therapeutic use , Hepatitis, Alcoholic/drug therapy , Protective Agents/therapeutic use , Silymarin/therapeutic use , Ursodeoxycholic Acid/therapeutic use , Adult , Aged , Drug Therapy, Combination , Hepatitis, Alcoholic/enzymology , Humans , Liver/enzymology , Male , Middle Aged , Treatment OutcomeABSTRACT
A dysfunction of dopaminergic systems with reduction of active dopamine, is well-known in cerebral involution. Twenty patients with mild-moderate pathological cerebral involution of atrophic and/or vascular origin, were treated with Selegiline (L-deprenyl), a monoamino-oxidase B inhibitor (10 mg/die for six months). Compared with a control group, Selegiline treated patients showed a statistically significant improvement in cognitive and behaviour capacities. At the end of investigation, "Mini Mental State" showed an improvement of 26.5% in Selegiline group and of 3.7% in control group (P < 0.01). "Echelle Clinique d'Aptitudes Intellectuelles" showed an improvement of 29.4% and of 10.8% respectively (P < 0.01). Selegiline treatment has shortened significantly the reaction times and has improved mnesic capacities. No side effects were observed during the study.
Subject(s)
Mental Disorders/drug therapy , Monoamine Oxidase Inhibitors/therapeutic use , Selegiline/therapeutic use , Aged , Cognition Disorders/diagnosis , Cognition Disorders/drug therapy , Female , Follow-Up Studies , Humans , Male , Memory Disorders/diagnosis , Memory Disorders/drug therapy , Mental Disorders/diagnosis , Mental Status Schedule , Monoamine Oxidase Inhibitors/administration & dosage , Placebos , Psychiatric Status Rating Scales , Psychological Tests , Psychometrics , Selegiline/administration & dosage , Time Factors , Treatment OutcomeABSTRACT
OBJECTIVES: This study investigated the prognostic value of left ventricular (LV) mass at echocardiography in uncomplicated subjects with essential hypertension. BACKGROUND: Only a few single-center studies support the prognostic value of LV mass in uncomplicated hypertension. METHODS: The MAssa Ventricolare sinistra nell'Ipertensione study was a multicenter (45 centers) prospective study. The prespecified aim was to explore the prognostic value of LV mass in hypertension. Admission criteria included essential hypertension, no previous cardiovascular events, and age > or =50. There was central reading of echocardiographic tracings. Treatment was tailored to the single subject. RESULTS: Overall, 1,033 subjects (396 men) were followed for 0 to 4 years (median, 3 years). Mean age at entry was 60 years, and systolic/diastolic blood pressure was 154/92 mm Hg. The rate of cardiovascular events (x100 patient-years) was 1.3 in the group with normal LV mass and 3.2 in the group (28.5% of total sample) with LV mass > or =125 g/body surface area (p = 0.005). After adjustment for age (p < 0.01), diabetes (p < 0.01), cigarette smoking (p < 0.01) and serum creatinine (p = 0.03), LV hypertrophy was associated with an increased risk of events (RR [relative risk] 2.08; 95% CI [confidence interval]: 1.22 to 3.57). For each 39 g/m(2) (1 SD) increase in LV mass there was an independent 40% rise in the risk of major cardiovascular events (95% CI: 14 to 72; p = 0.0013). CONCLUSIONS: Our findings show a strong, continuous and independent relationship of LV mass to subsequent cardiovascular morbidity. This is the first study to extend such demonstration to a large nationwide multicenter sample of uncomplicated subjects with essential hypertension.
Subject(s)
Cardiovascular Diseases/diagnostic imaging , Echoencephalography , Hypertension/diagnostic imaging , Hypertrophy, Left Ventricular/diagnostic imaging , Aged , Cardiovascular Diseases/mortality , Cause of Death , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/etiology , Female , Humans , Hypertrophy, Left Ventricular/mortality , Italy/epidemiology , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/mortality , Prognosis , Prospective Studies , Risk FactorsABSTRACT
We describe a patient with a microangiopathic hemolytic anemia, associated with thrombocytopenia, in consequence of breast cancer in an advanced phase. Microangiopathic hemolytic anemia is a rare and serious compliance of malignant neoplasms, in particular of breast and gastric carcinomas. Microangiopathic hemolytic anemia has always a serious prognosis: survivance in non-treated patients is of a few weeks. Our patient, treated by chemotherapy, has gained a partial remission of MHA, with a reduction of blood transfusions.